ChemoCentryx Inc. Common Stock (NASDAQ: CCXI)
Company Name:ChemoCentryx Inc. Common Stock
Stock Symbol:NASDAQ: CCXI
Class Period Start:11/26/2019
Class Period End (inclusive):05/06/2021
The Complaint alleges that the Company failed to disclose to investors that: (1) the study design of the Phase III ADVOCATE trial presented issues about the interpretability of the trial data to define a clinically meaningful benefit of avacopan and its role in the management of ANCA-associated vasculitis; (2) the data from the Phase III ADVOCATE trial raised serious safety concerns for avacopan; (3) these issues presented a substantial concern regarding the viability of ChemoCentryx’s NDA for avacopan for the treatment of ANCA associated vasculitis; and (4) as a result of the foregoing, Defendants’ public statements were materially false and misleading at all relevant times.